跳至主要内容
临床试验/NCT00072098
NCT00072098终止1 期

Phase I Trial Of Adenoviral Vector Delivery Of The Human Interleukin-12 cDNA By Intratumoral Injection In Patients With Metastatic Colorectal Cancer To The Liver

Max Sung1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2003年9月最近更新:
适应症

试验速览

阶段
1 期
状态
终止
发起方
入组人数
22
试验地点
1
主要终点
safety measure

研究概览

简要总结

RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body build an immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12 gene when injected into the tumors of patients with liver metastases secondary to colorectal cancer.

详细描述

OBJECTIVES:

  • Determine the toxicity and maximum tolerated dose of intratumoral adenoviral vector-delivered interleukin-12 gene in patients with liver metastases secondary to colorectal cancer .
  • Determine the tumor response in patients treated with this regimen.
  • Determine the immune response in patients treated with this regimen.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

safety measure

时间窗: up to day 57

adverse event reporting

toxicity grading

时间窗: up to day 57

toxicity will assessed from grades 0 to 4 as per common toxicity criteria

次要结局

  • tumor response compared at four weeks to baseline(baseline and four weeks)

研究者

发起方
Max Sung
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Max Sung

Associate Professor

Icahn School of Medicine at Mount Sinai

研究点 (1)

Loading locations...

相似试验